Goldman Urology Clinic has reached a cumulative total of 6,000 surgeries for benign prostatic hyperplasia (BPH), once again demonstrating its extensive clinical experience and treatment expertise. The achievement is attributed to the clinic’s continued application of personalized treatment strategies based on a wide range of surgical options tailored to each patient’s condition.
Benign prostatic hyperplasia is commonly seen in middle-aged and older men. As the prostate enlarges excessively, it compresses the urethra and causes lower urinary tract symptoms such as frequent urination, nocturia, a sensation of incomplete bladder emptying, and delayed urination. In the early stages, symptoms can often be managed with medication. However, when medication becomes less effective or symptoms repeatedly worsen, surgical treatment may become necessary. In such cases, physicians must consider not only the size and shape of the prostate but also the patient’s symptoms, the presence of complications, underlying chronic diseases, anesthesia considerations, and recovery planning in order to guide patients toward the most appropriate treatment method.
Based on these principles, Goldman Urology Clinic has focused on introducing advanced surgical techniques and refining its clinical protocols. These include Rezūm therapy, which injects high-temperature steam to induce necrosis and shrink enlarged prostate tissue; Aquablation, a robotic waterjet surgery that uses high-pressure water guided by an AI-based system to precisely remove prostate tissue without thermal damage; and Holmium Laser Enucleation of the Prostate (HoLEP), which removes enlarged prostate tissue using a holmium laser.
The clinic also provides additional treatment options such as the iTind device, which expands the prostatic urethra, and the UroLift system, which minimizes the burden associated with surgical tissue removal. By offering multiple treatment methods, the clinic has developed a personalized treatment strategy tailored to each patient’s prostate size, anatomical structure, and symptom severity.
In addition, Goldman Urology Clinic continues to conduct research on benign prostatic hyperplasia based on more than two million accumulated clinical cases over more than 20 years. These research efforts have translated into clinical outcomes in real-world practice and have received positive evaluations. For example, the clinic has presented research findings related to robotic waterjet surgery at academic conferences and has continuously evaluated and refined the safety and effectiveness of new surgical techniques in actual clinical settings.
Dr. Lee Chang-gi, CEO of Goldman Urology Clinic, explained that the outcomes of BPH surgery depend on several factors, including the experience of the medical team, the accuracy of preoperative evaluation, and the quality of postoperative management systems. He noted that physicians across all branches of Goldman Urology Clinic regularly share clinical data and collaborate to improve treatment protocols, enhancing consistency and safety in patient care.
He also emphasized that benign prostatic hyperplasia affects patients differently. Because each patient experiences different symptoms and may have different accompanying conditions or recovery plans, relying on a single treatment method as a universal solution is not appropriate. Instead, he explained that the key principle is to recommend the most suitable procedure at the appropriate time according to each patient’s individual condition and treatment needs.